Company intelligence / Profile preview

Samsung Biologics

Incheon/Songdo, South Koreaen.wikipedia.org ↗

Ownership: Public · KRX:207940
Employees: ~2587
Development stage: Commercial

Overview

Samsung Biologics operates at commercial scale with the world’s largest single-location biomanufacturing capacity. It has supported numerous client programs from preclinical through commercial stages with over twenty regulatory inspections and nearly thirty approvals in four years. The company maintains a strong record of manufacturing reliability and quality compliance.

Therapeutic areas: Other
Modalities: Monoclonal antibodies (mAbs)Bispecific antibodiesmRNA therapeuticsAntibody-drug conjugates (ADCs)Other biologics produced via mammalian cell culture
Industry: Contract Manufacturing Organization

Partnerships

Bristol Myers Squibb (BMS)RocheVir BiotechnologyGenerate Biosciences investment/collaborationMultiple global pharma companies as contract clients

Beyond the preview

Go deeper on Samsung Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Samsung Biologics.

Explore the full profile